{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1234.50","meta":{"versionId":"10","lastUpdated":"2022-01-06T01:02:20.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.50","version":"20220106","name":"COVID19 vaccine codes for exposure identification","status":"active","date":"2022-01-06T01:02:20-05:00","publisher":"BEST System Steward","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.42"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.44"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.43"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75"]}]},"expansion":{"identifier":"urn:uuid:8518849c-72bb-4c63-adb0-13a5071069ba","timestamp":"2022-06-10T06:39:20-04:00","total":28,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.ama-assn.org/go/cpt","code":"0001A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose"},{"system":"http://www.ama-assn.org/go/cpt","code":"0002A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose"},{"system":"http://www.ama-assn.org/go/cpt","code":"0003A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose"},{"system":"http://www.ama-assn.org/go/cpt","code":"0011A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose"},{"system":"http://www.ama-assn.org/go/cpt","code":"0012A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose"},{"system":"http://www.ama-assn.org/go/cpt","code":"0013A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose"},{"system":"http://www.ama-assn.org/go/cpt","code":"0031A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, single dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"207","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"208","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"210","display":"SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"212","display":"SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"213","display":"SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"217","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"218","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20220412","code":"219","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"2468235","display":"SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"2470234","display":"SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"2479835","display":"SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"2583743","display":"SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.05 MG/ML Injectable Suspension"},{"system":"http://www.ama-assn.org/go/cpt","code":"91300","display":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use"},{"system":"http://www.ama-assn.org/go/cpt","code":"91301","display":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use"},{"system":"http://www.ama-assn.org/go/cpt","code":"91303","display":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW013S6","display":"Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW013T6","display":"Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW013U6","display":"Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW023S6","display":"Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW023T6","display":"Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW023U6","display":"Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6"}]}}